Literature DB >> 31960231

Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.

Janelle L Lennie1,2, John T Mondick3, Marc R Gastonguay3,4.   

Abstract

Duchenne muscular dystrophy (DMD) is a rare X-linked genetic pediatric disease characterized by a lack of functional dystrophin production in the body, resulting in muscle deterioration. Lower body muscle weakness progresses to non-ambulation typically by early teenage years, followed by upper body muscle deterioration and ultimately death by the late twenties. The objective of this study was to enhance the quantitative understanding of DMD disease progression through nonlinear mixed effects modeling of the population mean and variability of the 6-min walk test (6MWT) clinical endpoint. An indirect response model with a latent process was fit to digitized literature data using full Bayesian estimation. The modeling data set consisted of 22 healthy controls and 218 DMD patients from one interventional and four observational trials. The model reasonably described the central tendency and population variability of the 6MWT in healthy subjects and DMD patients. An exploratory categorical covariate analysis indicated that there was no apparent effect of corticosteroid administration on DMD disease progression. The population predicted 6MWT began to rise at 1.32 years of age, plateauing at 654 meters (m) at 17.2 years of age for the healthy population. The DMD trajectory reached a maximum of 411 m at 8.90 years before declining and falling below 1 m at age 18.0. The model has potential to be used as a Bayesian estimation and posterior simulation tool to make informed model-based drug development decisions that incorporate prior knowledge with new data.

Entities:  

Keywords:  6-Min walk test; Bayesian estimation; Disease progression model; Duchenne muscular dystrophy; Rare disease

Mesh:

Substances:

Year:  2020        PMID: 31960231     DOI: 10.1007/s10928-020-09671-7

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  44 in total

1.  Bayesian model of disease progression in GNE myopathy.

Authors:  M Quintana; J Shrader; C Slota; G Joe; J C McKew; M Fitzgerald; W A Gahl; S Berry; N Carrillo
Journal:  Stat Med       Date:  2018-12-03       Impact factor: 2.373

2.  The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.

Authors:  Craig M McDonald; Erik K Henricson; Jay J Han; R Ted Abresch; Alina Nicorici; Leone Atkinson; Gary L Elfring; Allen Reha; Langdon L Miller
Journal:  Muscle Nerve       Date:  2010-12       Impact factor: 3.217

3.  Scientists rise up against statistical significance.

Authors:  Valentin Amrhein; Sander Greenland; Blake McShane
Journal:  Nature       Date:  2019-03       Impact factor: 49.962

4.  Bayesian clinical trial design using historical data that inform the treatment effect.

Authors:  Matthew A Psioda; Joseph G Ibrahim
Journal:  Biostatistics       Date:  2019-07-01       Impact factor: 5.899

5.  Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM.

Authors:  K Klingels; A G Mayhew; E S Mazzone; T Duong; V Decostre; U Werlauff; E Vroom; E Mercuri; N M Goemans
Journal:  Dev Med Child Neurol       Date:  2016-09-26       Impact factor: 5.449

6.  Second-generation compound for the modulation of utrophin in the therapy of DMD.

Authors:  Simon Guiraud; Sarah E Squire; Benjamin Edwards; Huijia Chen; David T Burns; Nandini Shah; Arran Babbs; Stephen G Davies; Graham M Wynne; Angela J Russell; David Elsey; Francis X Wilson; Jon M Tinsley; Kay E Davies
Journal:  Hum Mol Genet       Date:  2015-05-01       Impact factor: 6.150

7.  Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.

Authors:  Lora Hamuro; Phyllis Chan; Giridhar Tirucherai; Malaz AbuTarif
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-08-29

8.  Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.

Authors:  Caroline Brard; Lisa V Hampson; Nathalie Gaspar; Marie-Cécile Le Deley; Gwénaël Le Teuff
Journal:  BMC Med Res Methodol       Date:  2019-04-24       Impact factor: 4.615

Review 9.  Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges.

Authors:  Yusuke Echigoya; Kenji Rowel Q Lim; Akinori Nakamura; Toshifumi Yokota
Journal:  J Pers Med       Date:  2018-12-07

10.  6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes.

Authors:  Marika Pane; Elena S Mazzone; Maria Pia Sormani; Sonia Messina; Gian Luca Vita; Lavinia Fanelli; Angela Berardinelli; Yvan Torrente; Adele D'Amico; Valentina Lanzillotta; Emanuela Viggiano; Paola D'Ambrosio; Filippo Cavallaro; Silvia Frosini; Luca Bello; Serena Bonfiglio; Roberta Scalise; Roberto De Sanctis; Enrica Rolle; Flaviana Bianco; Marlene Van der Haawue; Francesca Magri; Concetta Palermo; Francesca Rossi; Maria Alice Donati; Chiara Alfonsi; Michele Sacchini; Maria Teresa Arnoldi; Giovanni Baranello; Tiziana Mongini; Antonella Pini; Roberta Battini; Elena Pegoraro; Stefano C Previtali; Sara Napolitano; Claudio Bruno; Luisa Politano; Giacomo P Comi; Enrico Bertini; Lucia Morandi; Francesca Gualandi; Alessandra Ferlini; Nathalie Goemans; Eugenio Mercuri
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more
  3 in total

1.  Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy.

Authors:  Xiaonan Li; Laurie S Conklin; John van den Anker; Eric P Hoffman; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2020-05-20       Impact factor: 3.126

Review 2.  Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.

Authors:  Kelley M Kidwell; Satrajit Roychoudhury; Barbara Wendelberger; John Scott; Tara Moroz; Shaoming Yin; Madhurima Majumder; John Zhong; Raymond A Huml; Veronica Miller
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303

3.  Bayesian modeling and simulation to inform rare disease drug development early decision-making: Application to Duchenne muscular dystrophy.

Authors:  Janelle L Lennie; John T Mondick; Marc R Gastonguay
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.